FOLH1 and prostate carcinoma: Prostate specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) has the capability to detect metastatic disease more accurately than conventional imaging in both the recurrent and primary setting [10,11], substantially impacting the management of patients with prostate cancer [12].